Prot# Tibotec TMC114-C202: A Phase II Randomized, Controlled, Partially Blinded, 48-Week Trial to Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced, Multi PI-Experienced HIV-1 Infected Subjects

Project: Research project

Project Details

StatusFinished
Effective start/end date2/9/04 → 8/12/08

Funding

  • Inveresk Research, Inc. (Tibotec TMC114-C202)
  • Tibotec Pharmaceuticals Ltd. (Tibotec TMC114-C202)